IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâ€™s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâ€™s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	$0.000100	0.00%	3,999
03/09/26	$0.000100	+9,900.00%	69,303
02/09/26	$0.000001	0.00%	611
01/09/26	$0.000001	0.00%	21,000
31/08/26	$0.000001	-99.00%	11,731

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 23:48:48 04/09/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-99.98%

08-19	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine	RE
04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI

Market Cap	43.81M 37.7M 35.47M 32.4M 60.61M 4.14B 60.78M 419M 163M 2.12B 165M 161M 6.84B	P/E 2023	-0.95x	P/E 2024	-0.63x
Enterprise Value	-14.31M -12.31M -11.58M -10.58M -19.79M -1.35B -19.85M -137M -53.11M -693M -53.72M -52.55M -2.23B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99.69%	Yield 2023 *	-	Yield 2024	-

08-19	Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine	RE
04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI
03-31	Io Biotech Inc - files voluntary chapter 7 bankruptcy petition on March 31, 2026 - SEC filing	RE
03-31	IO Biotech, Inc. Terminates Amy Sullivan as Chief Financial Officer on March 31, 2026	CI
03-31	IO Biotech, Inc. Announces Termination of Mai-Britt Zocca as Chief Executive Officer	CI
03-31	IO Biotech, Inc. Announces Management Changes on March 31, 2026	CI
02-17	CNS Pharmaceuticals, Inc. Announces Executive Appointments, Effective March 2, 2026	CI
01-31	Biotech, Inc. Announces Departure of Qasim Ahmad as Chief Medical Officer and Executive Officer, Effective February 15, 2026	CI
01-30	IO Biotech, Inc. Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic Alternatives	CI
01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-21	Io Biotech announces exploration of strategic alternatives	RE

01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT
30/09/25	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
30/09/25	TD Cowen Downgrades IO Biotech to Hold From Buy	MT

IO Biotech, Inc. Stock

Stocks

IOBTQ

US4497781090

Biotechnology & Medical Research

Valuation : IO Biotech, Inc.

Chart: IO Biotech, Inc.

Latest news : IO Biotech, Inc.

Last Transcript : IO Biotech, Inc.

Analysts' recommendations : IO Biotech, Inc.

Press Releases : IO Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : IO Biotech, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

02-02	IO Biotech Provides Corporate Update	AQ
01-30	IO Biotech Provides Corporate Update	AQ
01-21	IO Biotech Announces Exploration of Strategic Alternatives	AQ
12-16	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
11-26	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ

Current month	+9,900.00%
3 months	-98.78%
6 months	-99.97%
Current year	-99.98%

1 week	0		0
1 month	0		0
Current year	0		0.7
1 year	0		2.08
3 years	0		2.79
5 years	0		17.88
10 years	0		17.88

Manager	Title	Age	Since
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	01/10/2021
Devin Smith CMP	Compliance Officer	58	23/01/2023
Maryann Cimino IRC	Investor Relations Contact	-	01/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
05/06/25	Heidi Hunter	Free	Director	35,144	0.0533%
05/06/25	David Smith	Free	Director	35,144	0.0533%
05/06/25	Helen Collins	Free	Director	35,144	0.0533%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IO BIOTECH, INC.	0.00%	0.00%	-99.99%	-99.99%	7.19K
LONZA GROUP AG	-0.99%	-2.53%	-1.44%	+14.13%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+46.82%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-1.65%	-1.41%	+11.89%	+30.99%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	-0.74%	+0.48%	+54.53%	+86.78%	27.5B
Weighted average by Cap.	-0.79%	+0.11%	+89.37%	+128.89%

	2023	2024
Net sales	-	-
Net income	-86.08M -74.07M -69.69M -63.67M -119M -8.13B -119M -824M -320M -4.17B -323M -316M -13.43B	-95.49M -82.17M -77.31M -70.62M -132M -9.02B -132M -914M -355M -4.63B -359M -351M -14.9B
Net Debt	-141M -121M -114M -104M -195M -13.28B -195M -1.35B -522M -6.82B -528M -517M -21.96B	-58.12M -50.01M -47.05M -42.98M -80.41M -5.49B -80.62M -556M -216M -2.82B -218M -213M -9.07B